Published: Sun, March 05, 2017
Health Care | By Jeffery Armstrong

Juno Therapeutics Inc (JUNO) Given a $30.00 Price Target at FBR & Co

Juno Therapeutics Inc (JUNO) Given a $30.00 Price Target at FBR & Co

The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.61) by $0.04. SG Americas Securities LLC's holdings in Juno Therapeutics were worth $789,000 as of its most recent filing with the SEC.

Several other research analysts have also weighed in on JUNO. Vetr now has $22.32 price objective on the biopharmaceutical company's stock. Advisor Group Inc. increased its position in shares of Juno Therapeutics by 51.4% in the third quarter. Commerzbank Aktiengesellschaft FI acquired a new stake in Juno Therapeutics during the fourth quarter valued at approximately $192,000. NY boosted its stake in Juno Therapeutics by 397.3% in the second quarter. Advisor Group Inc. now owns 3,815 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 1,296 shares in the last quarter. NY now owns 4,441 shares of the biopharmaceutical company's stock worth $171,000 after buying an additional 3,548 shares in the last quarter.

11/28/2016 - Juno Therapeutics, Inc. had its " rating reiterated by analysts at Leerink Swann. Rockefeller Financial Services Inc. boosted its stake in shares of Juno Therapeutics by 1,433.2% in the third quarter. (JUNO) . Average true range (ATR-14) of the company is at 1.15.

Juno Therapeutics has conceded defeat on lead CAR-T therapy JCAR015, terminating its trial in leukaemia patients after five deaths. In order to determine directional movement, the 50-day and 200-day moving averages for Juno Therapeutics, Inc. The company's market cap is $2.21 billion.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Juno Therapeutics Inc.as 10.2 Million. Juno Therapeutics had a negative return on equity of 22.10% and a negative net margin of 445.86%. The difference between the expected and actual EPS was $-0.04/share, which represents an Earnings surprise of -6.6%. Juno Therapeutics's revenue was up 409.6% compared to the same quarter past year. On average, equities analysts predict that Juno Therapeutics will post ($2.84) EPS for the current year.

After the first deaths were reported Juno indicated the problem lay with a fludarabine-containing pre-conditioning regimen used to prepare patients for the CAR-T procedure, which involves an infusion of modified CAR-T cells that have been engineered to attack tumour cells. By placing estimates on the earnings of a firm for certain periods (quarterly, annually, etc), analysts can then use cashflow analysis to approximate a fair value for a company, which in turn will give a target share price for publicly traded companies.

11/23/2016 - Juno Therapeutics, Inc. had its " rating reiterated by analysts at BTIG Research.

Juno Therapeutics, Inc. was downgraded to " by analysts at Wells Fargo. Finally, SunTrust Banks, Inc. lowered shares of Juno Therapeutics from a "buy" rating to a "hold" rating and cut their price target for the stock from $48.00 to $25.00 in a report on Friday, November 25th. Stock's minimum price target estimates has been figured out at $23 while the maximum price target forecast is established at $41, if we look at the price target with an optimistic approach it has upside potential of 62% from its latest closing price of $25.31. Given that liquidity is king in short-term, JUNO is a stock with 109.23 million shares outstanding that normally trades 19.63% of its float.

The stock closed in the green Wednesday, after Juno beat Wall Street expectations on both the top and bottom lines, but it pared back those gains Thursday morning as investors learned of the discontinuation of JCAR015.

Like this: